These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34485608)

  • 1. Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency.
    Fañanas-Baquero S; Quintana-Bustamante O; Dever DP; Alberquilla O; Sanchez-Dominguez R; Camarena J; Ojeda-Perez I; Dessy-Rodriguez M; Turk R; Schubert MS; Lattanzi A; Xu L; Lopez-Lorenzo JL; Bianchi P; Bueren JA; Behlke MA; Porteus M; Segovia JC
    Mol Ther Methods Clin Dev; 2021 Sep; 22():237-248. PubMed ID: 34485608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene editing of PKLR gene in human hematopoietic progenitors through 5' and 3' UTR modified TALEN mRNA.
    Quintana-Bustamante O; Fañanas-Baquero S; Orman I; Torres R; Duchateau P; Poirot L; Gouble A; Bueren JA; Segovia JC
    PLoS One; 2019; 14(10):e0223775. PubMed ID: 31618280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency.
    Garcia-Gomez M; Calabria A; Garcia-Bravo M; Benedicenti F; Kosinski P; López-Manzaneda S; Hill C; Del Mar Mañu-Pereira M; Martín MA; Orman I; Vives-Corrons JL; Kung C; Schambach A; Jin S; Bueren JA; Montini E; Navarro S; Segovia JC
    Mol Ther; 2016 Aug; 24(7):1187-98. PubMed ID: 27138040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme.
    Meza NW; Alonso-Ferrero ME; Navarro S; Quintana-Bustamante O; Valeri A; Garcia-Gomez M; Bueren JA; Bautista JM; Segovia JC
    Mol Ther; 2009 Dec; 17(12):2000-9. PubMed ID: 19755962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo expression of human erythrocyte pyruvate kinase in erythroid cells: a gene therapy approach.
    Meza NW; Quintana-Bustamante O; Puyet A; Rio P; Navarro S; Diez A; Bueren JA; Bautista JM; Segovia JC
    Hum Gene Ther; 2007 Jun; 18(6):502-14. PubMed ID: 17547515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment.
    Navarro S; Quintana-Bustamante O; Sanchez-Dominguez R; Lopez-Manzaneda S; Ojeda-Perez I; Garcia-Torralba A; Alberquilla O; Law K; Beard BC; Bastone A; Rothe M; Villanueva M; Ramirez JC; Fañanas-Baquero S; Nieto-Romero V; Molinos-Vicente A; Gutierrez S; Nicoletti E; García-Bravo M; Bueren JA; Schwartz JD; Segovia JC
    Mol Ther Methods Clin Dev; 2021 Sep; 22():350-359. PubMed ID: 34514027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells.
    Garate Z; Quintana-Bustamante O; Crane AM; Olivier E; Poirot L; Galetto R; Kosinski P; Hill C; Kung C; Agirre X; Orman I; Cerrato L; Alberquilla O; Rodriguez-Fornes F; Fusaki N; Garcia-Sanchez F; Maia TM; Ribeiro ML; Sevilla J; Prosper F; Jin S; Mountford J; Guenechea G; Gouble A; Bueren JA; Davis BR; Segovia JC
    Stem Cell Reports; 2015 Dec; 5(6):1053-1066. PubMed ID: 26549847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Editing for Inherited Red Blood Cell Diseases.
    Quintana-Bustamante O; Fañanas-Baquero S; Dessy-Rodriguez M; Ojeda-Pérez I; Segovia JC
    Front Physiol; 2022; 13():848261. PubMed ID: 35418876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The variable manifestations of disease in pyruvate kinase deficiency and their management.
    Al-Samkari H; Van Beers EJ; Kuo KHM; Barcellini W; Bianchi P; Glenthøj A; Del Mar Mañú Pereira M; Van Wijk R; Glader B; Grace RF
    Haematologica; 2020 Sep; 105(9):2229-2239. PubMed ID: 33054048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
    Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
    Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Family Affected by a Life-Threatening Erythrocyte Defect Caused by Pyruvate Kinase Deficiency With Normal Iron Status: A Case Report.
    Maciak K; Adamowicz-Salach A; Poznanski J; Gora M; Fronk J; Burzynska B
    Front Genet; 2020; 11():560248. PubMed ID: 33193643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1.
    Schiroli G; Ferrari S; Conway A; Jacob A; Capo V; Albano L; Plati T; Castiello MC; Sanvito F; Gennery AR; Bovolenta C; Palchaudhuri R; Scadden DT; Holmes MC; Villa A; Sitia G; Lombardo A; Genovese P; Naldini L
    Sci Transl Med; 2017 Oct; 9(411):. PubMed ID: 29021165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression.
    Diez A; Gilsanz F; Martinez J; Pérez-Benavente S; Meza NW; Bautista JM
    Blood; 2005 Sep; 106(5):1851-6. PubMed ID: 15870173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation in a 3-year-old boy with congenital pyruvate kinase deficiency: A case report.
    Ma ZY; Yang X
    World J Clin Cases; 2021 Apr; 9(12):2916-2922. PubMed ID: 33969077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
    Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
    Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
    Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
    Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9 Gene Editing of Hematopoietic Stem Cells from Patients with Friedreich's Ataxia.
    Rocca CJ; Rainaldi JN; Sharma J; Shi Y; Haquang JH; Luebeck J; Mali P; Cherqui S
    Mol Ther Methods Clin Dev; 2020 Jun; 17():1026-1036. PubMed ID: 32462051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful allogeneic bone marrow transplantation using immunosuppressive conditioning regimen for a patient with red blood cell transfusiondependent pyruvate kinase deficiency anemia.
    Shimomura M; Doi T; Nishimura S; Imanaka Y; Karakawa S; Okada S; Kawaguchi H; Kobayashi M
    Hematol Rep; 2020 May; 12(1):8305. PubMed ID: 32499904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alu element insertion in PKLR gene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients.
    Lesmana H; Dyer L; Li X; Denton J; Griffiths J; Chonat S; Seu KG; Heeney MM; Zhang K; Hopkin RJ; Kalfa TA
    Hum Mutat; 2018 Mar; 39(3):389-393. PubMed ID: 29288557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.